Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Jurkat human T cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Nuclear Factor of activated T Cells (NFAT) (2) 5-HT Receptor (1) Akt (1) AP-1 (1) Apoptosis (4) CD28 (1) CD38 (1) Cyclophilin (1) Dihydroorotate Dehydrogenase (1) Dipeptidyl Peptidase (1) Galectin (1) HCV (1) HIV (2) HSP (1) IFNAR (4) IMPDH (1) Integrin (1) Interleukin Related (6) Itk (1) JAK (1) MAP4K (2) nAChR (1) NF-κB (3) p38 MAPK (1) PARP (1) PD-1/PD-L1 (4) PI3K (1) PROTACs (1) RIP kinase (1) Sigma Receptor (1) Src (1) TNF Receptor (2) Trk Receptor (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (9) Metabolic Disease (1) Neurological Disease (3)

By Targets:

Nuclear Factor of activated T Cells (NFAT) (2)

5-HT Receptor (1)

Akt (1)

AP-1 (1)

Apoptosis (4)

CD28 (1)

CD38 (1)

Cyclophilin (1)

Dihydroorotate Dehydrogenase (1)

Dipeptidyl Peptidase (1)

Galectin (1)

HCV (1)

HIV (2)

HSP (1)

IFNAR (4)

IMPDH (1)

Integrin (1)

Interleukin Related (6)

Itk (1)

JAK (1)

MAP4K (2)

nAChR (1)

NF-κB (3)

p38 MAPK (1)

PARP (1)

PD-1/PD-L1 (4)

PI3K (1)

PROTACs (1)

RIP kinase (1)

Sigma Receptor (1)

Src (1)

TNF Receptor (2)

Trk Receptor (1)

By Research Areas:

Cancer (16)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (9)

Metabolic Disease (1)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-173011

RJS308	PROTACs Cyclophilin HIV HCV	Infection
RJS308 is a selective Cyclophilin A (CypA) PROTAC degrader. RJS308 induces ubiquitin-dependent CypA degradation by recruiting the VHL E3 ligase complex, and forms a ternary complex with CypA and VHL/elongin C/elongin B. RJS308 exhibits anti-HIV-1 and anti-HCV activities. RJS308 can be used in studies related to viral infections .

HY-B0072

Tropisetron 4 Publications Verification SDZ-ICS-930 free base	5-HT Receptor nAChR p38 MAPK NF-κB AP-1 Nuclear Factor of activated T Cells (NFAT) JAK	Neurological Disease Inflammation/Immunology Cancer
Tropisetron is an orally active 5-HT3R antagonist (K_i = 5.3 nM) as well as being a potent and selective α7 nicotinic partial agonist (EC₅₀ = 1.3 μM). Tropisetron prevents phosphorylation and activation of the p38 MAPK. Tropisetron inhibits both IL-2 gene transcription and IL-2 synthesis in stimulated T cells. Tropisetron inhibits the binding to DNA and the transcriptional activity of NFAT and AP-1. Tropisetron is anti-inflammatory and antiemetic. Tropisetron has antitumor and neuroprotective effects. Tropisetron can be studied in research for diseases including hemorrhagic cystitis, chronic joint inflammation, lung cancer and chronic cerebral hypoperfusion .

HY-175287

α5β1 integrin agonist-2	Integrin	Cancer
α5β1 integrin agonist-2 (Compound 2) is a selective α5β1 integrin agonist (EC₅₀ = 45.98 nM). α5β1 integrin agonist-2 induces integrin activation. α5β1 integrin agonist-2 is applicable to the research of leukemia .

HY-P1684

Peptide P60 1 Publications Verification FOXP3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 ⁺CD25 ⁺Foxp3 ⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .

HY-174830

GJ19	PD-1/PD-L1	Cancer
GJ19 is a PD-L1 inhibitor with an IC₅₀ of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with K_d values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy .

HY-14622B

Necrostatin 2 (S enantiomer)	RIP kinase	Cardiovascular Disease Neurological Disease
Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2 (HY-14622). Necrostatin 2 S enantiomer inhibits TNF-α-induced necroptosis in Jurkat T cells. Necrostatin 2 S enantiomer can be used for the research of ischemic brain injury (stroke) .

HY-164548

WK88-1	HSP Apoptosis PI3K Akt NF-κB	Inflammation/Immunology Cancer
WK88-1 is an apoptosis inducer and Hsp90 client protein inhibitor with antiproliferative and immunomodulatory activities. WK88-1 inhibits signaling pathways such as PI3K/Akt and NF-κB, and induces mitochondrial dysfunction and cell cycle arrest. WK88-1 effectively suppresses cancer cell migration and invasion, and reverses various EGFR mutations and resistance to Gefitinib (HY-50895). WK88-1 also regulates the differentiation of monocytes and dendritic cells, blocks the expression of multiple chemokines, inhibits immune cell migration and M1 marker transcription, and restores impaired endocytic activity. WK88-1 has been used in studies of breast cancer, non-small cell lung cancer with various EGFR mutations or Met amplification, and atherosclerosis and other related diseases .

HY-118917

VX-148	IMPDH	Inflammation/Immunology
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with K_i values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .

HY-157469

TNT-i NPD3064	HIV	Infection
TNT-i (NPD3064) is an inhibitor targeting M-Sec. TNT-i inhibits M-Sec-induced tunneling nanotube (TNT) formation reversibly. TNT-i reduces wild-type HIV-1 production in macrophages and M-Sec-expressing T cells. TNT-i shows low cytotoxic effects on macrophages and T cells. TNT-i can be used for the research of HIV-1 infection .

HY-172107

HPK1-IN-56	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC₅₀: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC₅₀: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-162643

Antitumor agent-169	PD-1/PD-L1 PARP	Cancer
Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC₅₀s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with K_i of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics .

HY-N0990

1,5,15-Trimethylmorindol	Others	Cancer
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .

HY-181648

Gal-1-IN-1	Galectin Apoptosis	Cancer
Gal-1-IN-1 is a potent and selective human galectin-1 (hGal-1) inhibitor with a K_i of 0.022 μM. Gal-1-IN-1 blocks hGal-1 binding to tumor cells and suppresses human galectin-1-induced pre-apoptosis state. Gal-1-IN-1 reduces hGal-1-expressing cancer cell viability. Gal-1-IN-1 can be used for the research of breast cancer .

HY-181507

CD28-IN-3	CD28 IFNAR TNF Receptor Interleukin Related	Cancer
CD28-IN-3 is a CD28 inhibitor with an IC₅₀ of 7.80 μM and a Kd of 52.45 μM. CD28-IN-3 selectively blocks the CD28-B7 interaction, thereby inhibiting CD28-mediated costimulation. CD28-IN-3 suppresses the production of proinflammatory cytokines IFN-γ, IL-2 and TNF-α. CD28-IN-3 can be used in the research of checkpoint-resistant cancers .

HY-183887

PD-L1-IN-11	PD-1/PD-L1	Cancer
PD-L1-IN-11 is a PD-L1 inhibitor with human PD-L1 IC₅₀ and K_D of 27.82 μM and 49.50 μM, respectively. PD-L1-IN-11 directly binds to PD-L1 via a dimer-locking mechanism, occluding the PD-1 interaction surface to disrupt PD-1/PD-L1 interaction. PD-L1-IN-11 can be used for the research of melanoma, colon carcinoma .

HY-182335

PF-07245303	Itk Trk Receptor Interleukin Related IFNAR	Inflammation/Immunology
PF-07245303 is a ITK/TRK inhibitor. PF-07245303 reduces the production of inflammatory cytokines such as IL-4 and IFNγ, and inhibits the phosphorylation of PLCγ1. PF-07245303 inhibits nerve growth factor-induced basophil activation and the phosphorylation of TRKA. PF-07245303 reduces oxazolone-induced ear swelling in mouse ear tissues. PF-07245303 is applicable to research related to atopic dermatitis .

HY-N19727

Chamissonolide	Interleukin Related IFNAR TNF Receptor Apoptosis	Infection Cancer
Chamissonolide is a sesquiterpene lactone with cytotoxic, anti-inflammatory and trypanocidal activities. Chamissonolide reduces the mRNA levels of IL-2, IFN-γ, GM-CSF, iNOS and TNF-α, and upregulates the mRNA level of NF-ATc. Chamissonolide decreases the population of naturally occurring apoptotic cells. Chamissonolide can be used in research related to tumors, African trypanosomiasis and Chagas disease .

HY-182550

Indoluidin D	Dihydroorotate Dehydrogenase	Cancer
Indoluidin D is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with a human DHODH IC₅₀ of 210 nM. Indoluidin D selectively inhibits human DHODH activity, with induced effects rescuable by orotic acid. Indoluidin D promotes myeloid differentiation and inhibits cancer cell proliferation. Indoluidin D can be used for the research of acute promyelocytic leukemia .

HY-186178

CD38-IN-6	CD38	Metabolic Disease Inflammation/Immunology
CD38-IN-6 is an orally active CD38 inhibitor. CD38-IN-6 regulates NAD ⁺ metabolite levels in the liver of aged obese mice by increasing NAD ⁺ and NMN levels, and decreasing NAM and ADPR levels. CD38-IN-6 alleviates inflammatory responses in mice. CD38-IN-6 can be used for research related to obesity and inflammation .

HY-182374

AX8819	Dipeptidyl Peptidase Apoptosis	Cancer
AX8819 is a selective dipeptidyl peptidase II (DPP II) inhibitor with an IC₅₀ of 0.88 nM. AX8819 induces caspase-dependent apoptosis. AX8819 exhibits low non-specific toxicity toward proliferating T cells. AX8819 can be used for the research of B cell chronic lymphocytic leukemia .

HY-N15339A

Convolamine hydrochloride	Sigma Receptor	Neurological Disease
Convolamine hydrochloride is a tropane alkaloid and a potent Sigma-1 receptor positive allosteric modulator with an IC₅₀ value of 289 nM. Convolamine hydrochloride can be extracted from Convolvulus plauricalis. Convolamine hydrochloride exhibits cognitive-improving and neuroprotective properties. Convolamine hydrochloride can be used in research related to Wolfram syndrome and Alzheimer's disease .

HY-112448

Lck-IN-6	Src Interleukin Related	Inflammation/Immunology
Lck-IN-6 (Compound 12g) is a Lck inhibitor with an IC₅₀ of 3 nM. Lck-IN-6 inhibits the production of IL-2. Lck-IN-6 can be used in the research of rheumatoid arthritis and inflammatory bowel disease .

Cat. No.	Product Name	Target	Research Area